Virus-Like Particle & Nano-Particle Vaccines

28-30 November 2012, Novotel Montfleury Cannes, Cannes, France

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Virus-like particles are supra-molecular assemblages incorporating key immunologic features of viruses which include repetitive surfaces, particulate structures with potential for induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors. They carry no replicative genetic information and can be produced in heterologous expression systems at large scale. Virus-like particles thus represent a safe and effective vaccine platform with potential to induce potent B- and T-cell responses. In addition to being effective vaccines against the corresponding viruses from which they are derived, virus-like particles can also be used to present foreign epitopes to the immune system. This can be achieved by genetic fusion or chemical conjugation. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases. Towards this end, virus-like particles have been used to induce auto-antibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer’s disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development.

VLPNPV 2012 is a new forum for international researchers working on Virus-Like Particles (VLPs) the multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, and Nano-Particles potentially yielding safer and cheaper vaccine candidates. A small number of prophylactic VLP-based vaccines are currently commercialized worldwide: GlaxoSmithKline’s Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.’s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This new meeting will focus on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production will be important for process control, monitorization and optimization. VLP-based and NP-based vaccines updates will be presented with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.

VLPNPV 2012 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.

Scientific Advisory Panel

Martin Bachmann (University of Zurich, Zurich, Switzerland)
Bryce Chackerian (University of New Mexico, Albuquerque, New Mexico, USA)
Marc-Andre D’Aoust (Medicago Inc., Quebec, Canada)
Greg Glenn (Novavax Inc., Rockville, Maryland, USA)
Melissa M. Herbst-Kralovetz (University of Arizona, Phoenix, Arizona, USA)
David J.M. Lewis (St. George’s University of London, UK)
George Lomonossoff (John Innes Centre, Norwich, UK)
Marianne Manchester (University of California, San Diego, California, USA)
Ann Meyers (University of Cape Town, South Africa)
Trudy Morrison (University of Massachusetts, Worcester, Massachusetts, USA)
Peter Pushko (Medigen Inc., Frederick, Maryland, USA)
Charles Richardson (LigoCyte Pharmaceuticals Inc., Bozeman, Montana, USA)
Ted Ross (University of Pittsburgh, Pittsburgh, Pennsylvania, USA)
Polly Roy (London School of Hygiene & Tropical Medicine, London, UK)
Geert Vanden Bossche (Smart Vaccine Technologies LLC, Seattle, Washington, USA)
Brian Ward (McGill University, Montreal, Quebec, Canada)
Vidadi Yusibov (Fraunhofer USA, Newark, Delaware, USA)
Richard Compans (Emory University, Atlanta, Georgia, USA)
Adriana Baz Morelli (CSL Limited, Parkville, Victoria, Australia)
Alan Shaw (Vedantra Corporation, Cambridge Massachusetts, USA)

Conference Scope

  • Virus-Like Particle Vaccines
  • VLP Vaccine Manufacturing
  • Nano-Particles and Nano-Particulate Vaccines
  • VLP Platforms as Delivery Systems for Therapeutics, Imaging and Antigen Presentation
  • Structure (non-enveloped, enveloped and synthetic)
  • Formulation and Stability of VLP and Nano-Particulate Vaccines and Adjuvants
  • Delivery Systems (including Microneedles)
  • VLP Expression Systems (Baculovirus, Cell Culture, Yeast, Plants)
  • Safety and Regulatory Issues (regulation of expression systems)
  • HepB
  • HPV
  • Influenza
  • Developing VLP Candidates
  • Clinical Trials Updates
  • ISCOMs & ISCOMATRIX
  • Chitosan Particles
  • Liposomes
  • VLPs as Protein Delivery Systems
  • VLPs for Drug Delivery
  • Novel Applications (eg Cell-Free Synthesis)
  • Nanotechnology Approaches (Non-Conventional VLPs)
  • Particulate-Based Vaccines
 

VLPNPV 2012 Delegates

Login details will be supplied after you have registered for the event.


VLPNPV 2012 Sponsors

  • European Adjuvant Advisory Committee
  • UMN
  • Aldevron
  • Medigen
  • Pevion Vaccines
  • Sanofi Pasteur
  • University of Tampere Vaccine Research Center
  • John Innes Centre
  • Nature Gene Therapy
  • Viscogel
  • Fraunhofer
  • Medicago
  • Nanosight
  • Novavax
  • Isconova
  • Mucosis
  • Ligocyte
  • MSD
  • Izon

VLPNPV 2012 Downloads

VLPNPV 2012 Leaflet

VLPNPV 2012 Mailing List

Name
E-mail Address
What is 1+4-2?